



Twelfth Annual Congress of
**THE EGYPTIAN SOCIETY
FOR THE GLAUCOMAS**

4-5 October, 2012
Le Méridien Hotel, Heliopolis, Cairo, Egypt

www.glaucoma-egypt.org
www.esg-conferences.com

Scientific Program



LUMIGAN®



President's

WELCOME ADDRESS



President of the ESG,
Professor Zeinab M. Osman

Dear Colleagues,

On behalf of the members of the Egyptian Society for the Glaucomas (ESG) and the organizing committee, it is my great pleasure to welcome you all to the 12th Annual Meeting of the society, to be held at the Heliopolis Meridien hotel on 4-5 October, 2012.

A first step toward achieving this is that we, the glaucoma specialists, take this year's meeting as an opportunity to share knowledge and exchange ideas, which would hopefully reflect on improved diagnostic and treatment modalities, for the ultimate benefit of glaucoma patients.

As our success depends on your attendance and contribution, we hope that you join us.

Zeinab Osman

W E M E

E W E E M



Twelfth Annual Congress of
THE EGYPTIAN SOCIETY FOR THE GLAUCOMAS

Founders of the ESG

Honorary President of the ESG,
Mohamed I. ABDALLA

Honorary Vice President of the ESG,
Nabeel SABRI

Members of Board

President
Zeinab M. OSMAN

Vice President
Adel ABDELSHAFIK

Secretary
Moustafa K. NASSAR

Treasurer
Adel ABDELRAZIK

Members*:
Mohamed I. ABDALLA
Gamal ABDELLATIF
Ahmed I. ABOULEINEIN
Abdallah F. EL-SAWY
Ayman EL SHIATY
Laila M. HAMOUDA
Taha A. LABIB
Ali KHALIFA
Ahmed K. KHALIL
Tharwat Mokbeel
Nabeel I. SABRI

* in Alphabetical order

Organizing Committee

President
Zeinab M. OSMAN

Vice president
Adel ABDELSHAFIK

Secretary
Moustafa K. NASSAR

Treasurer
Adel ABDELRAZIK

Scientific Committee*:
Adel ABDELSHAFIK
Ahmed I. ABOULEINEIN
Ayman EL SHIATY
Laila M. HAMOUDA
Ahmed K. KHALIL

* in Alphabetical order

Congress shall include

- ◎ Free Courses.
- ◎ Interaction Session.
- ◎ Eminent Guest Speakers.
- ◎ Symposia on:
 - Basics of glaucoma diagnosis
 - Early detection of glaucoma
 - Different types of glaucoma presentation
 - Medical treatment of glaucoma
 - Role of laser in glaucoma management
 - Surgical treatment of glaucoma
 - Secondary glaucomas





COMBIGAN® – a different class of treatment

An effective adjunct for Maximal Medical Therapy*



Combigan

(betamethasone tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%



GENERAL INFORMATION

Registration:

- Registration fees for Non Egyptian: 100 USD
- Registration fees for Members of ESG: 20 L.E.
(already covering membership fees of previous years).
- Registration fees for Non-ESG members: 100 L.E.
(Registration fees covers attending the scientific sessions, coffee breaks tickets).

Lunch:

- ESG Members: 40 L.E.
- Non-ESG Members: 100 L.E.

Gala Dinner:

Gala Dinner Tickets: 70 L.E.

Early reservation is necessary

All attendees must wear their Name Tag all through the conference. Admission to the conference halls will only be with the Name Tag and scanning of the attendees Barcode.

Certificates will be given on Friday upon showing the Name Tag of the Conference, without the conference Name Tag, the certificate will not be handled.

Speakers are kindly requested to handle their presentations ONE HOUR prior the start of their sessions. No personal laptops will be allowed to be used inside halls. Some of the presentations of the meeting may be recorded and distributed to the members of the society.


A different class in the treatment of glaucoma



First choice for patients with low-tension glaucoma
to slow rate of progression

Alphagan P
brimonidine tartrate ophthalmic solution 0.15%

The difference is clear



THURSDAY

4 October 2012

09:30	Instruction Courses I
12:15	Coffee Break
12:45	Symposium I
14:15	Save Sight Years (Allergan)
15:00	Lunch
16:00	Symposium II
17:10	Panel Discussion
20:00	Gala Dinner

FRIDAY

5 October 2012

09:30	Instruction Courses II
11:45	Fixed Combination (Alcon)
12:00	Gomaa Prayer & Lunch
14:00	Save Sight Years (Allergan)
14:30	Symposium III
16:30	Symposium IV

SCIENTIFIC PROGRAM

W E M E

E W E E M



09:30-12:15

Instruction Course
Glaucoma Diagnosis

09:30 | IOP.

H. Eissa

A. El-Shaity

10:00 | Gonioscopy.

A. Abdelshafik

H. El Ibiary

A. Saleh

10:45 | Optic Disc.

A. Khalifa

A. Abouleinein

11:15 | Posterior Segment Imaging.

L. Hamouda

Z. ElSanabary

k. Raafat

A. Ismail



THURSDAY
4 October 2012

12:45-14:15

Symposium I
Glaucoma Management

Chairpersons: Taha Labib, Zafer Fahim, Hassan Eissa

12:45 | Target pressure & uveoscleral outflow.

Taha Labib

**13:00 | Is target IOP equal in bilaterally
glaucomatous patients?**

Ali M. Ismail

13:10 | Challenges in glaucoma.

Tharwat Mokbeel

**13:25 | Gene therapy in glaucoma
management.**

Mohamed Mahdy

**13:40 | Role of the pharmacist in glaucoma:
Empowering the patient.**

Sherif Hosny

13:50 | Pseudoglaucomatous optic disc.

Abdalla El-Sawy

M. Abd El-wahed

14:05 | Discussion.



14:15-15:00

Save Sight Years (SSY)



ALLERGAN

16:00 -17:10

Symposium II

Lasers in Glaucoma

Mostafa Nabih, Zeinab Osman, Abdel khalik El Sadani

16:00 | Management of Neovascular Glaucoma With Panretinal Photocoagulation, Intravitreal Bevacizumab, and Subsequent Trabeculectomy With Mitomycin C.

Ayman Alkawas

16:10 | SLT in pseudophakic eyes.

Rasha ElTanamly

16:25 | Diode laser CPC for POAG

Mohamed El-Malah

16:35 | Trabeculectomy with photodynamic therapy (BCECF-AM) vs trabeculectomy with antimetabolite (MMC) in POAG.

Ahmed Saeed

16:45 | Lost anterior chamber after a cyclodestructive procedure.

Mostafa Nabih

17:00 | Discussion.

17:15-18:00

Panel

Angle Closure Glaucoma

Moderator: Laila Hammouda

Panelists:

Adel Abdelshafik

Ahmed Abouleinein

Hassan Eisa

Ali Khalifa

Zeinab Osman

Breaks

12:15-12:45
Coffee Break

15:00-16:00
Lunch

20:00
Gala Dinner

09:30-11:45

Instruction Course Glaucoma Management

09:30 | Perimetry.

*M.Nassar
F.wagdi
M.sami*

10:15 | Trabeculectomy.

*A. Abouleinein
A. Abdelrazik
M. Mahdy*

11:00 | Challenge of Glaucoma in the Infant.

*A. Khalil
M. El-Sada
N. Bayoumi*



FRIDAY

5 October 2012

11:45-12:00

Fixed combination **Alcon**[®]
a Novartis company

14:00-14:30

Save Sight Years (SSY)
 **ALLERGAN**

14:30 - 16:25

Symposium III | Glaucoma Surgery

Chairpersons: Ahmad Khalil, Saber Hamed,
Abdelaziz Ryad

14:30 | Trabeculectomy with Ologen for POAG.
Mohamed El-Malah

14:40 | Vitreous tapping during glaucoma surgery.
Mohamed ElBasty

14:55 | Repeat trabeculectomy.
Ahmed Mostafa Abdelrahman

15:10 | Early Post trabeculectomy hypotony is a risk factor for glaucoma failure.
Ali Ismail

15:20 | Evaluation of Glaucoma Bleb at the Early Postoperative Period.
Adel Abdelshafik

15:35 | The Overhanging Bleb & Hypotony Syndrome, management & intermediate term follow up.
Ahmad Khalil

15:50 | Phacotrabeculectomy.
Said Shalaby

16:05 | Phacoemulsification vs combined phacotrabeculectomy with adjunctive mitomycin C in treatment of medically controlled CACG with cataract.
Ahmed M. Saeed

16:15 | Discussion.

16:30 -18:00

Symposium IV

Paediatric glaucoma and valve surgery

Chairpersons: Adel Abdelshafik, Abdelaziz Saad,
Samiha Aboulmagd

16:30-16:45 | Pathological Angle changes in Congenital Glaucoma and its Implications in Indications of Surgery.

Tarek Ragaiey

16:45-17:00 | Viscotribeculectomy for paediatric glaucoma.

Hala ElHilaly

17:00-17:15 | Ahmed Valve implantation (technique & difficulties)

Adel Abdelshafik

17:15-17:30 | Pearls of Ahmed valve implant.

Ahmed Mostafa

17:30-17:45 | Valve Revision.

Cherif Zaazoo

17:45-18:00 | Corneoscleral rim patch for paediatric glaucoma Valves.

Yasmine M. El Sayed

Breaks

12:00-14:00
Gomaa Prayer
& Lunch





ALLERGAN

Dry Eye solutions
for all of your patients



optive

Restasis
Restasis is a registered trademark of Allergan, Inc.



GANfort 
(bimatoprost/timolol ophthalmic solution) 0.03%/0.5%





The power you need. The ocular comfort patients appreciate.

AZARGA® Suspension delivers the efficacy you expect
with the comfort patients want.

79.2%

of patients who stated a preference
preferred AZARGA® Suspension¹ –

Superior comfort compared to Dorzolamide/Timolol^{*1,2}

¹Based on patient preference.

Up to

35%

of IOP reduction from untreated baseline
in patients with open-angle glaucoma or
ocular hypertension³

**There's no reason to sacrifice
patient comfort.**

References:

1. Mundorf TK, Rauchman SH, Williams RD, Netivoli R. Brinzolamide/Timolol Preference Study Group. A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. *Clin Ophthalmol* 2008;2(3):623-628. 2. Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. Brinzolamide/Timolol Comfort Study Group. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. *J Ocul Pharmacol Ther* 2008;24(6):601-605. 3. Manni G, Denis P, Chow P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. *J Glaucoma* 2009;18(4):293-300.

Please see Summary of Product Characteristics on adjacent page.

*Trademark is the property of its owner.

Alcon

© 2011 Novartis AG 4/11 AZG13003AD-0

WHERE STRENGTH MEETS COMFORT
AZARGA
(brinzolamide 10mg/ml + timolol 5mg/ml) eyedrops, suspension